Ignite Creation Date:
2024-05-06 @ 12:32 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03786692
Status:
RECRUITING
Last Update Posted:
2024-02-12
First Post:
2018-12-21
Brief Title:
Phase II Randomized Trial of CarboplatinPemetrexedBevacizumab- Atezolizumab in Stage IV NSCLC
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01
Completion Date Type:
ESTIMATED
First Submit Date:
2018-12-21
First Submit QC Date:
December 24 2018
Study First Post Date:
2018-12-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-09
Last Update Post Date:
2024-02-12
Last Update Post Date Type:
ACTUAL